QUARTERLY SUMMARY

JULY ’10-SEPTEMBER ‘10

Florida ADAP

AIDS Drug Assistance Program

Improving Health. . . Promoting Wellness

BREAKDOWN OF COUNTY HEALTH DEPARTMENTS BY PHARMACY CATEGORY



AIDS DRUG ASSISTANCE PROGRAM
AREA PRIMARY CONTACTS



West Region Consultant:
Stephanie Brown
850-245-4444, Ext. 2551

West Region:
Bay, Calhoun, Escambia, Franklin, Gadsden, Gulf, Holmes, Jackson, Jefferson, Leon, Liberty, Okaloosa, Palm Beach, Santa Rosa, Wakulla, Walton, Washington

Central Region Consultant:
Jimmy Llaque
850-245-4444, Ext. 2547

Central Region:
Brevard, Highlands, Indian River, Lake, Okeechobee, Orange, Osceola, Polk, Sarasota, Seminole, St. Lucie, Sumter, Volusia

East Region Consultant:
Makeshia Barnes
850-245-4444, Ext. 2549

East Region:
Alachua, Baker, Bradford, Clay, Citrus, Columbia, Dixie, Duval, Flagler, Gilchrist, Hamilton, Hernando Lafayette, Levy, Marion, Madison, Nassau, Pasco, Pinellas, Putnam, St. Johns, Sumter, Suwannee, Taylor, Union

South Region Consultant:
Alex Bello
850-245-4444, Ext. 2538

South Region:
Charlotte, Collier, Dade, Desoto, Glades, Hardee, Hendry, Lee, Manatee, Martin, Monroe, Sarasota

OTHER CONTACT INFORMATION

Administrative Secretary:
Brenda Andrews
850-245-4444, Ext. 2556

Database Analyst:
Eduardo Lourenco
850-245-4444, Ext. 2546

Client Service/Marketing Coordinator
Steven Badura
850-245-4444, Ext. 2552

Pharmacy Liaison:
Justin Ferrill
850-245-4444, Ext. 2504

CASELOAD BY YEAR (Page 1 of 2)

(Number of Clients 12,782)

NEW CLIENTS: 39

RE-OPENED CASES: 774

CLOSED CLIENTS: 1,526

	2008	2009	2010		2008	2009	2010
ALACHUA	91	125	116	ESCAMBIA	149	188	182
BAKER	5	4	4	FLAGLER	1	2	6
BAY	65	72	70	FRANKLIN	1	0	0
BRADFORD	2	4	2	GADSDEN	6	6	4
BREVARD	178	182	161	GILCHRIST	0	0	0
BROWARD	2,392	2,911	2,588	GULF	1	1	1
CALHOUN	0	0	0	HAMILTON	1	1	2
CHARLOTTE	34	46	42	HARDEE	7	5	3
CITRUS/ HERNANDO	62	64	55	HENDRY/GLADES	13	18	15
CLAY	18	24	17	HIGHLANDS	28	35	39
COLLIER	167	192	178	HILLSBOROUGH	634	818	768
COLUMBIA	9	17	10	HOLMES	2	4	3
MIAMI-DADE	3,195	3,566	3,386	INDIAN RIVER	44	58	48
DESOTO	17	14	15	JACKSON	13	24	15
DIXIE	3	3	4	JEFFERSON	0	0	0
DUVAL	560	733	621				

CASELOAD BY YEAR (Page 2 of 2)

(Number of Clients 12,782)

NEW CLIENTS: 39

RE-OPENED CASES: 774

CLOSED CLIENTS: 1,526

	2008	2009	2010		2008	2009	2010
LAFAYETTE	0	0	1	PASCO	45	74	65
LAKE	89	98	80	PINELLAS	406	487	443
LEE	215	245	212	POLK	282	335	268
LEON	154	196	147	PUTNAM	20	30	28
LEVY	5	6	2	SANTA ROSA	3	5	5
LIBERTY	0	0	0	SARASOTA	166	210	164
MADISON	4	7	0	SEMINOLE	86	94	101
MANATEE	124	142	155	ST. JOHNS	31	45	42
MARION	79	104	92	ST. LUCIE	125	142	150
MARTIN	47	44	51	SUMTER	13	8	11
MONROE	62	83	85	SUWANNEE	4	3	8
NASSAU	6	13	7	TAYLOR	2	6	6
OKALOOSA	42	54	61	UNION	0	0	1
OKEECHOBEE	12	13	10	VOLUSIA	124	168	134
ORANGE	746	956	815	WAKULLA	0	0	1
OSCEOLA	165	200	193	WALTON	0	0	0
PALM BEACH	980	1,141	1,087	WASHINGTON	4	3	2

STATEWIDE PICK-UP PERCENTAGE

July 1, 2010 – September 30, 2010



Statewide pick-up percentage is based on the total number of clients who picked-up at least once within the month.

CLIENT CD4 COUNT

July 1, 2010 – September 30, 2010



CLIENT VIRAL LOAD COUNT

July 1, 2010 – September 30, 2010



CD4/VL: The last value reported for enrolled clients within the quarter.

GENDER & RACE/ETHNICITY (12,782 CLIENTS)

July 1, 2010 – September 30, 2010





RACE/ETHNICITY OTHERS* (152 CLIENTS)



GENDER BY RACE/ETHNICITY

July 1, 2010 – September 30, 2010



MALE (9,308 clients)



FEMALE (3,450 clients)



Transgender clients represent less than 1% of the cases (24 clients); 14 Black Non-Hispanic, 5 White Non-Hispanic, and 5 Hispanic.

GENDER BY AGE

July 1, 2010 – September 30, 2010



REDUCED FORMULARY

As of August 1, 2010

ANTIRETROVIRALS (ARV's)

APTIVUS (Tipranavir)
ATRIPLA (Tenofovir/Emtricitabine/Efavirenz)
COMBIVIR (Zidovudine/Lamivudine)
CRIXIVAN (Indinavir)
EMTRIVA (Emtricitabine)
EPIVIR (Lamivudine)
EPZICOM (Abacavir/Lamivudine)
FUZEON (Enfuvirtide) 🗐
INTELENCE (Etravirine)
INVIRASE (Saquinavir)
ISENTRESS (Raltegravir)
KALETRA (Lopinavir/Ritonavir)
LEXIVA (Fosamprenavir)
NORVIR (Ritonavir)
PREZISTA (Darunavir)
RESCRIPTOR (Delavirdine)
RETROVIR (Zidovudine)
REYATAZ (Atazanavir)
SELZENTRY (Maraviroc) 🗐
SUSTIVA (Efavirenz)
TRIZIVIR (Abacavir/Lamivudine/Zidovudine)
TRUVADA (Tenofovir/Emtricitabine)
VIDEX (Didanosine)
VIRACEPT (Nelfinavir)
VIRAMUNE (Nevirapine)
VIREAD (Tenofovir)
ZERIT (Stavudine)
ZIAGEN (Abacavir)

OPPORTUNISTIC INFECTION (OIs)

BACTRIM DS (TMP/SMZ DS)
BIAXIN (Clarithromycin)
DARAPRIM (Pyrimethamine)
DAPSONE (Diamino-diphenyl Sulfone)
DIFLUCAN (Fluconazole)
LEUCOVORIN (Folinic Acid)
MEPRON (Atovaquone)
MONISTAT (Miconazole)
MYAMBUTOL (Ethambutol)
MYCELEX TROCHE (Clotrimazole)
MYCOBUTIN (Rifabutin)
NIZORAL (Ketoconazole)
SPORANOX (Itraconazole)
SULFADIAZINE
TERAZOL (Terconazole)
VALCYTE (Valganciclovir Hcl)
VALTREX (Valacyclovir)
ZITHROMAX (Azithromycin)
ZOVIRAX (Acyclovir)

Note to providers: For eligible ADAP clients who need to receive Hepatitis C treatment, please call Makeshia Barnes in the ADAP office at 850-245-4444, ext. 2549.

🗐 **Prior authorization only**

REDUCED FORMULARY BY CLASS

As of August 1, 2010

ANTIRETROVIRALS

NUCLEOS(T)IDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)

1. ATRIPLA (Tenofovir/Emtricitabine/Efavirenz)
2. COMBIVIR (Zidovudine/Lamivudine)
3. EMTRIVA (Emtricitabine)
4. EPIVIR (Lamivudine)
5. EPZICOM (Abacavir/Lamivudine)
6. HIVID (Zalcitabine)
7. RETROVIR (Zidovudine)
8. TRIZIVIR (Abacavir/Lamivudine/Zidovudine)
9. TRUVADA (Tenofovir/Emtricitabine)
10. VIDEX (Didanosine)
11. VIREAD (Tenofovir)
12. ZERIT (Stavudine)
13. ZIAGEN (Abacavir)

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI's)

1. INTELENCE (Etravirine)
2. RESCRIPTOR (Delavirdine)
2. SUSTIVA (Efavirenz)
3. VIRAMUNE (Nevirapine)

PROTEASE INHIBITOR (PIs)

1. APTIVUS (Tipranavir)
2. CRIXIVAN (Indinavir)
3. INVIRASE (Saquinavir)
4. KALETRA (Lopinavir/Ritonavir)
5. LEXIVA (Fosamprenavir)
6. NORVIR (Ritonavir)
7. PREZISTA (Darunavir)
8. REYATAZ (Atazanavir)
9. VIRACEPT (Nelfinavir)

FUSION/ENTRY INHIBITOR

FUZEON (Enfuvirtide) 🗐
SELZENTRY (Maraviroc) 🗐

INTEGRASE INHIBITOR

ISENTRESS (Raltegravir)

OPPORTUNISTIC INFECTION (OIs)

1. BACTRIM DS (TMP/SMZ DS)
2. BACTROBAN (Mupirocin)
3. BIAXIN (Clarithromycin)
4. DARAPRIM (Pyrimethamine)
5. DAPSONE (Diamino-diphenyl Sulfone)
6. DIFLUCAN (Fluconazole)
7. KETOCONAZOLE (Nizoral)
8. LEUCOVORIN (Folinic Acid)
9. MEPRON (Atovaquone)
10. MONISTAT (Miconazole)
11. MYAMBUTOL (Ethambutol)
12. MYCELEX TROCHE (Clotrimazole)
13. MYCOBUTIN (Rifabutin)
14. SPORANOX (Itraconazole)
15. SULFADIAZINE
16. TERAZOL (Terconazole)
17. VALCYTE (Valganciclovir Hcl)
18. VALTREX (Valacyclovir)
19. ZITHROMAX (Azithromycin)
20. ZOVIRAX (Acyclovir)

🗐 Prior authorization only

DRUGS DISPENSED BY CLASS

July 1, 2010 – September 30, 2010

*TOTAL: $34,332,994

NUCLEOS(T)IDE	$19,457,117	OPPORTUISTIC INFECTIONS	$395,197
NON-NUCLEOSIDE	$1,185,979	WASTING	$36,994
PROTEASE INHIBITOR	$9,660,088	NEUROPATHY	$24,233
ENTRY INHIBITOR	$164,141	ANEMIA/ NEUTROPENIA	$71,926
FUSION INHIBITOR	$86,059	OTHERS	$46,872
INTEGRASE INHIBITOR	$3,009,380	HEPATITIS	$96,862
HYPERLIPIDEMIA	$97,499	HYPERGLYCEMIA	$647

*This total represents the value of drugs ordered, not the actual usage for the quarter.

DRUGS DISPENSED BY PERCENTAGE

July 1, 2010 – September 30, 2010



Others include: Anemia/Neutropenia, Hyperlipidemia, Entry Inhibitor, Fusion Inhibitor, Wasting, Neuropathy, Hepatitis, and Hyperglycemia, Vaccine, Supplement.

TOP 10 DRUGS DISPENSED

July 1, 2010 – September 30, 2010



*****Two Drug Combination***

******Three Drug Combination***

SELZENTRY/TROFILE ASSAY

	1st Qtr (Apr-Jun)	2nd Qtr (Jul-Sep)
Trofile	10 Approved	10 Approved
Selzentry	5 Approved	3 Approved

TOP TEN DRUGS BY CLIENT USAGE

July 1, 2010 – September 30, 2010